Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk

Drugs under Experimental and Clinical Research

Volumn 30, Issue 5-6, 2004, Pages 191-195

  Rallis, E ^a,d   Nasiopoulou, A ^a   Kouskoukis, C ^b   Koumantaki, E ^c  

^a NIMTS HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; LACTAM DERIVATIVE; MACROLACTAM DERIVATIVE; PIMECROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FACE; FEMALE; HUMAN; MALE; MONOTHERAPY; RECURRENT DISEASE; SEBORRHEIC DERMATITIS; SKIN INFLAMMATION; SKIN IRRITATION; TRUNK;

ADOLESCENT; ADULT; DERMATITIS, SEBORRHEIC; FACE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OINTMENT BASES; PILOT PROJECTS; TACROLIMUS;

EID: 11444259305     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gupta A.K., Bluhm R., Cooper E.A., et al. Seborrheic dermatitis. Dermatol. Clin., 21(3), 401, 2003.
2. Zaidi Z., Wahid Z., Cochinwala R., et al. Correlation of the density of yeast Malassezia with the clinical severity of seborrheic dermatitis. J. Pak. Med. Assoc., 52(11), 504, 2002.
3. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol., 1(2), 75, 2000.
4. Gupta A.K., Nicol K.A. Seborrheic dermatitis of the scalp: Etiology and treatment. J. Drugs Dermatol., 3(2), 155, 2004.
5. Ling M.R. Topical tacrolimus and pimecrolimus: Future directions. Semin. Cutan. Med. Surg., 20(4), 268, 2001.
6. Wolff K., Stuetz A. Pimecrolimus for the treatment of inflammatory skin diseases. Expert Opin. Pharmacother., 5(3), 643, 2004.
7. Meshkinpour A., Sun J., Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol., 49, 145, 2003.
8. Braza T.J., DiCarlo J.B., Soon S.L., McCall C.O. Tacrolimus 0.1% ointment for seborrheic dermatitis: An open-label pilot study. Br. J. Dermatol., 148, 1242, 2003.
9. Brownell I., Quan L.T., Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol. Online J., 9(3), 13, 2003.
10. Crutchfield C.E. 3rd. Pimecrolimus: A new treatment for seborrheic dermatitis. Cutis, 70(4), 207, 2002.
11. Eichenfield L.F., Lucky A.W., Boguniewicz M., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol., 46, 495, 2002.
12. Meurer M., Folster-Holst R., Wozel G., et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology, 205, 271, 2002.
13. Marsland A.M., Griffiths C.E. The macrolide immunosuppressants in dermatology: Mechanisms of action. Eur. J. Dermatol., 12(6), 618, 2002.
14. Gupta A.K., Chow M. Pimecrolimus: A review. JEADV, 17, 493, 2003.
15. Stuetz A., Grassberger M., Meingassner J.G. Pimecrolimus (Elidel, SDZ ASM 981) - Preclinical pharmacologic profile and skin selectivity. Semin. Cutan. Med. Surg., 20(4), 233, 2001.
16. Luger T., Van Leent E.J.M., Graeber M., et al. SDZ ASM 981: An emerging safe and effective treatment of atopic dermatitis. Br. J. Dermatol., 144, 788, 2001.
17. Kalthoff F.S., Chung J., Musser P., Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin. Exp. Immunol., 133, 350, 2003.
18. Meingassner J.G., Kowalsky E., Schwendinger H., et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br. J. Dermatol., 149, 853, 2003.
19. Billich A., Aschauer H., Aszodi A., et al. Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int. J. Pharm., 269(1), 29, 2004.
20. Van Leent E., Ebelin M., Burtin P., et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology, 204, 63, 2002.
21. Thaci D., Steinmeyer K., Ebelin M., et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe and effective. Dermatology, 207, 37, 2003.